The North America Hemophilia Market would witness market growth of 5.2% CAGR during the forecast period (2023-2030).
The market is also anticipated to benefit from increasing funds for hemophilia research over the projected period. For instance, a multi-institutional project to develop hemophilia medications will be led by a researcher from the Indiana University School of Medicine in March 2022. This project is funded with USD 12 million from the National Heart, Lung, and Blood Institute. This will pave the way for the creation of cutting-edge hemophilia treatments, which is anticipated to propel the market's expansion over the anticipated time frame.
The market is primarily driven by the approval of gene therapy for the treatment of hemophilia and the existence of numerous other candidates in various pipeline stages. In addition, rising government support for programs aimed at early diagnosis in newborns and increased awareness of hemophilia disorders. Additionally, the expansion of the market is anticipated to be boosted by an increase in product approvals by the US Food and Drug Administration.
The therapeutic advances in hemophilia have resulted in a wave of new FDA-approved agents. Additionally, the rising consumer awareness about technologically advanced products, the rising prevalence of hemophilia, and the existence of a sizable patient pool are the main factors propelling the growth of the market in the region. In the United States, there were 18,398 hemophilia patients in 2021, comprising 14,098 hemophilia A and 4,300 cases of hemophilia B, according to the World Federation of Hemophilia 2021 study. According to the estimate, there were around 4050 hemophilia cases in Canada in 2021, including 3,323 hemophilia A and 727 cases of hemophilia B.
Due to the greater use of hemophilia therapeutics, the large number of hemophilia cases in these regions is anticipated to fuel market expansion. A gene for an inherited bleeding problem is carried by around 300,000 Canadians, according to the Canadian Hemophilia Society. At least 30,000 Canadians, or one in ten of these individuals, have symptoms severe enough to warrant medical attention. Many of them have received inadequate diagnoses. In the Canadian network of comprehensive care clinics for hereditary bleeding disorders, only 10,000 persons with inherited bleeding disorders are listed. As a result, throughout the forecast period, the market in this region is anticipated to be driven by rising research and development into the creation of new, effective medicines as well as rising hemophilia prevalence.
The US market dominated the North America Hemophilia Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $5,736.1 million by 2030. The Canada market is experiencing a CAGR of 7.6% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 6.6% during (2023 - 2030).
Based on Distribution Channel, the market is segmented into Specialty Pharmacies, and Hospital Pharmacies. Based on Type, the market is segmented into Hemophilia A, Hemophilia B, and Others. Based on Treatment Type, the market is segmented into Prophylaxis, On-demand, and Cure. Based on Therapy, the market is segmented into Factor Replacement Therapy (Recombinant Factor Concentrates, and Plasma-derived Factor Concentrates), Desmopressin & Fibrin Sealants, and Gene Therapy & Monoclonal Antibodies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Hemophilia Market is Projected to reach USD 18.3 Billion by 2030, at a CAGR of 6.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, CSL Limited (CSL Behring), Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB (Investor AB) and Sanofi S.A.
Scope of the Study
Market Segments Covered in the Report:
By Distribution Channel
- Specialty Pharmacies
- Hospital Pharmacies
By Type
- Hemophilia A
- Hemophilia B
- Others
By Treatment Type
- Prophylaxis
- On-demand
- Cure
By Therapy
- Factor Replacement Therapy
- Recombinant Factor Concentrates
- Plasma-derived Factor Concentrates
- Desmopressin & Fibrin Sealants
- Gene Therapy & Monoclonal Antibodies
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Takeda Pharmaceutical Company Limited
- CSL Limited (CSL Behring)
- Pfizer, Inc.
- Bayer AG
- F.Hoffmann-La Roche Ltd.
- Novo Nordisk A/S
- Octapharma AG
- BioMarin Pharmaceutical Inc.
- Swedish Orphan Biovitrum AB (Investor AB)
- Sanofi S.A.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Hemophilia Market, by Distribution Channel
1.4.2 North America Hemophilia Market, by Type
1.4.3 North America Hemophilia Market, by Treatment Type
1.4.4 North America Hemophilia Market, by Therapy
1.4.5 North America Hemophilia Market, by Country
1.5 Methodology for the research
Chapter 2. Market At a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Trials and Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Product Launches and Product Expansions : 2017, Jun – 2021, Jun) Leading Players
4.4 Porter Five Forces Analysis
Chapter 5. North America Hemophilia Market by Distribution Channel
5.1 North America Specialty Pharmacies Market by Country
5.2 North America Hospital Pharmacies Market by Country
Chapter 6. North America Hemophilia Market by Type
6.1 North America Hemophilia A Market by Country
6.2 North America Hemophilia B Market by Country
6.3 North America Others Market by Country
Chapter 7. North America Hemophilia Market by Treatment Type
7.1 North America Prophylaxis Market by Country
7.2 North America On-demand Market by Country
7.3 North America Cure Market by Country
Chapter 8. North America Hemophilia Market by Therapy
8.1 North America Factor Replacement Therapy Market by Country
8.2 North America Hemophilia Market by Factor Replacement Therapy Type
8.2.1 North America Recombinant Factor Concentrates Market by Country
8.2.2 North America Plasma-derived Factor Concentrates Market by Country
8.3 North America Desmopressin & Fibrin Sealants Market by Country
8.4 North America Gene Therapy & Monoclonal Antibodies Market by Country
Chapter 9. North America Hemophilia Market by Country
9.1 US Hemophilia Market
9.1.1 US Hemophilia Market by Distribution Channel
9.1.2 US Hemophilia Market by Type
9.1.3 US Hemophilia Market by Treatment Type
9.1.4 US Hemophilia Market by Therapy
9.1.4.1 US Hemophilia Market by Factor Replacement Therapy Type
9.2 Canada Hemophilia Market
9.2.1 Canada Hemophilia Market by Distribution Channel
9.2.2 Canada Hemophilia Market by Type
9.2.3 Canada Hemophilia Market by Treatment Type
9.2.4 Canada Hemophilia Market by Therapy
9.2.4.1 Canada Hemophilia Market by Factor Replacement Therapy Type
9.3 Mexico Hemophilia Market
9.3.1 Mexico Hemophilia Market by Distribution Channel
9.3.2 Mexico Hemophilia Market by Type
9.3.3 Mexico Hemophilia Market by Treatment Type
9.3.4 Mexico Hemophilia Market by Therapy
9.3.4.1 Mexico Hemophilia Market by Factor Replacement Therapy Type
9.4 Rest of North America Hemophilia Market
9.4.1 Rest of North America Hemophilia Market by Distribution Channel
9.4.2 Rest of North America Hemophilia Market by Type
9.4.3 Rest of North America Hemophilia Market by Treatment Type
9.4.4 Rest of North America Hemophilia Market by Therapy
9.4.4.1 Rest of North America Hemophilia Market by Factor Replacement Therapy Type
Chapter 10. Company Profiles
10.1 Swedish Orphan Biovitrum AB (Investor AB)
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expenses
10.1.5 SWOT Analysis
10.2 Takeda Pharmaceutical Company Limited
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Trials and Approvals:
10.2.5.2 Product Launches and Product Expansions:
10.3 Pfizer, Inc.
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Regional & Segmental Analysis
10.3.4 Research & Development Expense
10.3.4.1 Partnerships, Collaborations, and Agreements:
10.3.4.2 Acquisition and Mergers:
10.4 CSL Limited (CSL Behring)
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Trials and Approvals:
10.4.5.2 Acquisition and Mergers:
10.4.6 SWOT Analysis
10.5 Octapharma AG
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Research & Development Expenses
10.5.4 Recent strategies and developments:
10.5.4.1 Trials and Approvals:
10.5.5 SWOT Analysis
10.6 Bayer AG
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental and Regional Analysis
10.6.4 Research & Development Expense
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.6.5.2 Acquisition and Mergers:
10.6.6 SWOT Analysis
10.7 F. Hoffmann-La Roche Ltd.
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Segmental and Regional Analysis
10.7.4 Research & Development Expense
10.7.5 SWOT Analysis
10.8 Novo Nordisk A/S
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Segmental & Regional Analysis
10.8.4 Research & Development Expenses
10.8.5 Recent strategies and developments:
10.8.5.1 Partnerships, Collaborations, and Agreements:
10.8.5.2 Product Launches and Product Expansions:
10.8.5.3 Acquisition and Mergers:
10.8.6 SWOT Analysis
10.9 BioMarin Pharmaceutical Inc.
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Regional Analysis
10.9.4 Research & Development Expenses
10.9.5 Recent strategies and developments:
10.9.5.1 Trials and Approvals:
10.9.6 SWOT Analysis
10.10. Sanofi S.A.
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Segmental and Regional Analysis
10.10.4 Research & Development Expense
10.10.5 Recent strategies and developments:
10.10.5.1 Trials and Approvals:
TABLE 1 North America Hemophilia Market, 2019 - 2022, USD Million
TABLE 2 North America Hemophilia Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Hemophilia Market
TABLE 4 Product Launches And Product Expansions– Hemophilia Market
TABLE 5 Acquisition and Mergers– Hemophilia Market
TABLE 6 Trials and Approvals– Hemophilia Market
TABLE 7 North America Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 8 North America Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 9 North America Specialty Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 10 North America Specialty Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 11 North America Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 12 North America Hospital Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 13 North America Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 14 North America Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 15 North America Hemophilia A Market by Country, 2019 - 2022, USD Million
TABLE 16 North America Hemophilia A Market by Country, 2023 - 2030, USD Million
TABLE 17 North America Hemophilia B Market by Country, 2019 - 2022, USD Million
TABLE 18 North America Hemophilia B Market by Country, 2023 - 2030, USD Million
TABLE 19 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 20 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 21 North America Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 22 North America Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 23 North America Prophylaxis Market by Country, 2019 - 2022, USD Million
TABLE 24 North America Prophylaxis Market by Country, 2023 - 2030, USD Million
TABLE 25 North America On-demand Market by Country, 2019 - 2022, USD Million
TABLE 26 North America On-demand Market by Country, 2023 - 2030, USD Million
TABLE 27 North America Cure Market by Country, 2019 - 2022, USD Million
TABLE 28 North America Cure Market by Country, 2023 - 2030, USD Million
TABLE 29 North America Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 30 North America Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 31 North America Factor Replacement Therapy Market by Country, 2019 - 2022, USD Million
TABLE 32 North America Factor Replacement Therapy Market by Country, 2023 - 2030, USD Million
TABLE 33 North America Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 34 North America Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 35 North America Recombinant Factor Concentrates Market by Country, 2019 - 2022, USD Million
TABLE 36 North America Recombinant Factor Concentrates Market by Country, 2023 - 2030, USD Million
TABLE 37 North America Plasma-derived Factor Concentrates Market by Country, 2019 - 2022, USD Million
TABLE 38 North America Plasma-derived Factor Concentrates Market by Country, 2023 - 2030, USD Million
TABLE 39 North America Desmopressin & Fibrin Sealants Market by Country, 2019 - 2022, USD Million
TABLE 40 North America Desmopressin & Fibrin Sealants Market by Country, 2023 - 2030, USD Million
TABLE 41 North America Gene Therapy & Monoclonal Antibodies Market by Country, 2019 - 2022, USD Million
TABLE 42 North America Gene Therapy & Monoclonal Antibodies Market by Country, 2023 - 2030, USD Million
TABLE 43 North America Hemophilia Market by Country, 2019 - 2022, USD Million
TABLE 44 North America Hemophilia Market by Country, 2023 - 2030, USD Million
TABLE 45 US Hemophilia Market, 2019 - 2022, USD Million
TABLE 46 US Hemophilia Market, 2023 - 2030, USD Million
TABLE 47 US Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 48 US Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 49 US Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 50 US Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 51 US Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 52 US Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 53 US Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 54 US Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 55 US Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 56 US Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 57 Canada Hemophilia Market, 2019 - 2022, USD Million
TABLE 58 Canada Hemophilia Market, 2023 - 2030, USD Million
TABLE 59 Canada Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 60 Canada Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 61 Canada Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 62 Canada Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 63 Canada Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 64 Canada Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 65 Canada Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 66 Canada Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 67 Canada Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 68 Canada Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 69 Mexico Hemophilia Market, 2019 - 2022, USD Million
TABLE 70 Mexico Hemophilia Market, 2023 - 2030, USD Million
TABLE 71 Mexico Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 72 Mexico Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 73 Mexico Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 74 Mexico Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 75 Mexico Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 76 Mexico Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 77 Mexico Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 78 Mexico Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 79 Mexico Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 80 Mexico Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 81 Rest of North America Hemophilia Market, 2019 - 2022, USD Million
TABLE 82 Rest of North America Hemophilia Market, 2023 - 2030, USD Million
TABLE 83 Rest of North America Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 84 Rest of North America Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 85 Rest of North America Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 86 Rest of North America Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 87 Rest of North America Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 88 Rest of North America Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 89 Rest of North America Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 90 Rest of North America Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 91 Rest of North America Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 92 Rest of North America Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 93 Key Information – Swedish Orphan Biovitrum AB
TABLE 94 Key Information – Takeda Pharmaceutical Company Limited
TABLE 95 Key Information – Pfizer, Inc.
TABLE 96 Key Information – CSL Limited
TABLE 97 Key Information – Octapharma AG
TABLE 98 Key Information – Bayer AG
TABLE 99 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 100 Key Information – Novo Nordisk A/S
TABLE 101 Key Information – BioMarin Pharmaceutical Inc.
TABLE 102 Key Information – Sanofi S.A.
List of Figures
FIG 1 Methodology for the research
FIG 2 North America Hemophilia Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting the Hemophilia Market
FIG 4 KBV Cardinal Matrix
FIG 5 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 6 Key Strategic Move: (Product Launches and Product Expansions : 2017, Jun – 2021, Jun) Leading Players
FIG 7 Porter’s Five Forces Analysis –Hemophilia Market
FIG 8 North America Hemophilia Market share by Distribution Channel, 2022
FIG 9 North America Hemophilia Market share by Distribution Channel, 2030
FIG 10 North America Hemophilia Market by Distribution Channel, 2019 - 2030, USD Million
FIG 11 North America Hemophilia Market share by Type, 2022
FIG 12 North America Hemophilia Market share by Type, 2030
FIG 13 North America Hemophilia Market by Type, 2019 - 2030, USD Million
FIG 14 North America Hemophilia Market share by Treatment Type, 2022
FIG 15 North America Hemophilia Market share by Treatment Type, 2030
FIG 16 North America Hemophilia Market by Treatment Type, 2019 - 2030, USD Million
FIG 17 North America Hemophilia Market share by Therapy, 2022
FIG 18 North America Hemophilia Market share by Therapy, 2030
FIG 19 North America Hemophilia Market by Therapy, 2019 - 2030, USD Million
FIG 20 North America Hemophilia Market share by Country, 2022
FIG 21 North America Hemophilia Market share by Country, 2030
FIG 22 North America Hemophilia Market by Country, 2019 - 2030, USD Million
FIG 23 SWOT Analysis: Swedish Orphan Biovitrum AB
FIG 24 SWOT Analysis: CSL Limited
FIG 25 SWOT Analysis: Octapharma AG
FIG 26 SWOT Analysis: Bayer AG
FIG 27 SWOT Analysis: F. Hoffmann-La Roche Ltd.
FIG 28 Recent strategies and developments: Novo Nordisk A/S
FIG 29 SWOT Analysis: Novo Nordisk A/S
FIG 30 SWOT Analysis: BioMarin Pharmaceutical Inc.